Haemoglobin
Biomarker4 papers1 finding
- Human trial1
- Humans2
Interventions
1SGLT2 inhibitors
upin humans1+5%Very low certainty
1 study
SGLT2 inhibitors
upin humans1+5%Very low certainty
SGLT2 inhibitors increase haemoglobin in humans (+5.0%).
“Haemoglobin rose 5.0%, consistent with plasma-volume contraction.”
Humansinitiating an SGLT2 inhibitor6 monthsn = 54
Longitudinal Changes in Insulin Resistance Indices During SGLT2 Inhibitor Therapy in Type 2 Diabetes: A Prospective Single-Arm Cohort Study · Preprints.org · 28 Aug 2026 · Preprint
Latest
44Abdominal MRI-Derived Liver, Visceral Fat, and Pancreatic Phenotypes Improve Prediction of Incident Type 2 Diabetes
Orforglipron matches insulin glargine on cardiovascular safety
Over a median two years, major adverse cardiovascular events occurred in 4.2% of orforglipron participants compared with 5.0% of insulin glargine…Over a median two years, major adverse cardiovascular events occurred in 4.2% of orforglipron participants compared with 5.0% of insulin glargine controls.
Retatrutide reduces bodyweight in obesity and type 2 diabetes
Bodyweight fell by up to 18.8% with weekly retatrutide compared with 5.1% on placebo at week 80 in adults with obesity and type 2 diabetes.Bodyweight fell by up to 18.8% with weekly retatrutide compared with 5.1% on placebo at week 80 in adults with obesity and type 2 diabetes.